Trials / Completed
CompletedNCT04912050
EXtension of Tablo TrEatmeNt Duration Registry
EXtension of Tablo TrEatmeNt Duration Registry (XTEND)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Outset Medical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Tablo Hemodialysis System | Renal Replacement Therapy between 12\< to ≤ 24 hours. |
Timeline
- Start date
- 2021-05-25
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
- First posted
- 2021-06-03
- Last updated
- 2022-08-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04912050. Inclusion in this directory is not an endorsement.